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ABSTRACT  
Langerhans cell histiocytosis (LCH) is monoclonal neoplastic condition of aberrant bone marrow histiocytes.  The latter are part of the innate 
immune system and certain exogenous/endogenous stimuli may trigger its expansion.  Hence LCH can present with limited or multiple organ 
involvement that may include; bones, lung, endocrine, skin, lymph nodes, spleen and bone marrow.  In this case report, we describe a 3-year-old 
boy who presented with severe polyuria and polydipsia.  Laboratory investigations were consistent with diabetes insipidus (DI).  MRI of the 
brain; confirmed absence of the bright spot in his pituitary gland did not show evidence of tumor or enlargement by inflammation.  Moreover, 
MRI revealed 2 skull lesions and their subsequent biopsy confirmed LCH.  Systemic examination and tests including PET scan did not show 
additional lesions.  Since his disease was localized, he received only Desmopressin acetate 120 ug twice daily for his DI without surgery, 
radiotherapy or chemotherapy.  One year later, his disease remained limited to DI and the 2 bonny lesions.   
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INTRODUCTION 
Diabetes insipidus (DI) is a disorder characterized by 
polydipsia and polyuria due to lack or ineffective antidiuretic 
hormone (ADH).  The latter is produced by the hypothalamus 
and is stored in posterior lobe of pituitary gland (PG) 1.  ADH 
is released, if serum hyperosmolality is sensed by the 
hypothalamus, to prevent urinary water loss 2.  Hence, the 
disorder can result from; (a) cranial (PG/hypothalamus) 
disease and (b) nephrogenic resistance to its action.  The 
most common causes of cranial DI are; (a) idiopathic (30%), 
(b) malignant or benign tumors of the brain or PG (25%), (c) 
cranial surgery (20%), and head trauma (16%).  Rare 
etiologies include; genetic familial disorders, toxins, 
infections, sarcoidosis, hemochromatosis, amyloidosis, 
autoimmune hypophysitis and Langerhans cell histiocytosis 
(LCH) 3. The latter is an extremely rare neoplastic disorder of 
tissue histiocytes with variable phenotypic presentation 
from localized disease to an overwhelming malignant disease 
4.  In this case report, we describe a patient presenting with 
DI and localized bonny lesions and highlight his 
management.   
CASE REPORT: 
A 3-year-boy presented with history of excessive thirst and 
urination including wetting his bed at night for 1 year.    The 
patient did not have past history of significant medical 
illness, allergy or chronic intake of medications.  He did not 
have similar problem in his family members.  His initial 
physical examination did not show abnormality. Laboratory 
tests showed normal peripheral leucocytic and platelets 
counts.  Hemoglobin was normal at 120 g/L.  Serum sugar, 
urea, creatinine, electrolytes and liver functions were 
normal.  Urine routine and microscopy did not show 
abnormality.  Chest x-ray and ECG were normal.  Ultrasound 
of the abdomen and pelvis was normal.  His 24-hour urine 
volume was 6 liters.  Night serum osmolality was 310 
mmol/L (N: 275-290) with urine osmolality at 100 mmol/L.  
He could not tolerate water overnight water restriction for 
polydipsia.  Early morning ADH level was undetectable (N: 
0.9 to 4.6 pmol/L).  Tests of the function of anterior PG 
function showed normal results.  They included; insulin 
hypoglycemia for stimulation of growth hormone, TSH, T3, 
T4, 8 AM serum cortisol, FSH, LH, testosterone and prolactin.  
Moreover, he had normal levels of renin and aldosterone.  
MRI of the brain showed normal-sized pituitary gland and its 
stalk yet with abscent posterior pituitary bright spot on pre-
enhanced T1W1 images (Fig. 1).  In addition; MRI showed 2 
soft tissue skull-based lesions, in the right frontoparietal and 
left occipital regions, which enhanced on contrast study (Fig. 
2).  Biopsy of the occipital lesion revealed large histiocytes 
with reniform and grooved nuclei with indistinct nucleoli 
and eosinophilic cytoplasm scattered among an infiltrate of 
lymphocytes, eosinophils, and macrophages (Fig. 3).  On 
special stains, those large histiocytes were immunoreactive 
for antibodies directed against CD1a and S100 protein 
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confirming LCH 5.  PET-CT scan did not show additional 
lesions.  He was treated with Minerin melt 120 ug twice 
daily.  Within few days, he showed significant improvement 
in his thirst, appetite, enuresis, activity and had gained 
adequate weight.  One week later; 24 hour urine volume as 
well as serum and urine osmolality were normal.  Since his 
DI was controlled and his bonny lesions were small and 
limited; he was not subjected to surgical excision of lesions, 
radiotherapy or chemotherapy.  One year later; he remained 
stable while on Minirin melt.  PET-CT scan did not show new 
bonny lesions or expansion of the previous ones. 
  
 
Figure 1: Pre-contrast coronal T1-weighted MRI view showing normal size of the pituitary gland and its stalk (A).  Note absence 
of posterior pituitary bright spot in sagittal view (B). 
 
Figure 2: Axial Views of MRI of brain T1FS+CFC showing contrast enhancing skull lesions in the (A) right fronto-parietal and (B) 
left occipital areas. 
 
Figure 3: Photomicrograph of the bonny lesion showing large histiocytes with reniform and grooved nuclei with indistinct 
nucleoli and eosinophilic cytoplasm scattered among an infiltrate of lymphocytes, eosinophils, and macrophages (H&E X 400). 
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DISCUSSION 
Our patient presented with polyuria with low urine 
osmolality and high serum osmolality indicating DI.  The high 
serum osmolality excluded primary (psychogenic) polydipsia 
6.  Moreover, undetectable ADH and correction of polyuria, 
serum and urine osmolality after Desmopressin therapy 
confirmed diagnosis of cranial DI 7.  In search for the etiology 
of cranial DI; MRI was done.  In our patient, it confirmed; the 
abscence of the “bright spot” which correlates with the 
secretory granules in the posterior lobe and ruled out 
abnormalities in the PG and its stalk induced by tumors and 
hypophysitis 8.  Moreover, MRI revealed 2 incidental soft 
tissue masses in his skull.  Biopsy of the occipital one 
disclosed LCH and ruled out bonny metastasis.  LCH is a rare 
disease arising from immature myeloid dendritic cells in the 
bone marrow rather than from epidermal Langerhans cells.  
Evidence of its monoclonicity was reported more than 20 
years ago, supporting the notion that LCH is a neoplastic 
process 9.  More recently, the identification of 
oncogenic BRAF V600E mutations in 25% to 64% of cases of 
LCH has provided additional evidence that LCH is a neoplasm 
10.  It occurs most often in children and in white individuals 
of northern European ancestry 4.  The broad clinical 
spectrum that is encompassed by LCH is reflected in the 
many synonyms for this disease, which include eosinophilic 
granuloma (unifocal LCH), Hand-Shüller-Christian disease 
(multifocal unisystem LCH), and Letterer-Siwe disease 
(disseminated multifocal multisystem LCH).  In single-
system LCH, bone is the most common site of involvement 
followed by skin, lymph node, spleen, bone marrow and lung 
4.  Pulmonary LCH seems to be a distinct entity, as it occurs 
almost exclusively in smokers and may resolve with 
cessation of smoking 11.  Liver, spleen, and bone marrow are 
considered “risk organs involvement” and are associated 
with high risk of mortality 4.  Management of LCH is tailored 
to match the sites of involvement and extent of disease.  Such 
strategy was based on the concept of disease induction and 
progression in relation to exogenous/endogenous stimuli 
since histiocytes are part of innate immunity system.  For 
treatment purposes, patients with LCH are generally 
stratified into; (a) single-system or multisystem, and (b) high 
or low-risk organ involvement 12.  Chemotherapy for patients 
with low-risk multisystem LCH is 1 year of vinblastine and 
prednisone compared to an additional mercaptopurine in the 
high-risk group.  On the other hand; children with bonny 
lesions rarely need more than curettage and may even 
regress spontaneously 13.  Our patient had central DI which is 
the most frequent CNS manifestation of LCH, occurring in 
10–50% of all patients 14.  However, and on follow up; 30– 
58% of those patients manifest anterior pituitary hormone 
deficiencies which seems to be linked to a thickening of the 
pituitary stalk 15.  Moreover, they can also develop 
neurodegenerative disease 16.  Our patient had cranial DI and 
2 skull lesions.  His physical examination, laboratory 
investigations, radiological and PET scans did not show 
evidence of other systemic disease.  Since he had limited 
disease; we elected to treat him conservatively and avoid 
chemotherapy.  Fortunately, and after 1 year of follow up; he 
did not manifest further expansion of his disease.    
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